Zdrowie i gospodarka · 21.10.1997
Guidance for Industry on SUPAC-IR: Immediate Release Solid Oral Dosage Forms, Manufacturing Equipment Addendum; Availability
The Food and Drug Administration (FDA) is announcing the availability of a Level 1 guidance for industry entitled ``SUPAC-IR: Immediate Release Solid Oral Dosage Forms--Manufacturing Equipment Addendum.'' This guidance is intended to provide insight and recommendations to pharmaceutical sponsors of new drug applications (NDA's), abbreviated new drug applications (ANDA's), and abbreviated antibiotic applications (AADA's) who wish to change equipment during the postapproval period. This guidance document represents the agency's current thinking on scale-up and postapproval equipment changes (SUPAC) for immediate release dosage forms regulated by the Center for Drug Evaluation and Research (CDER).